SCYNEXIS, Inc.

SCYX

Healthcare|Medical - Pharmaceuticals|US

$3.50

+0.20 (+6.06%)

Tangible Book / Share

$4.99

Cash / Share

$3.98

Clinical Trials (18)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT05399641 Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis	Vulvovaginal Candidiasis	P3	Completed	150	RCT, Open-label	Ibrexafungerp
NCT03734991 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)	Candida Vulvovaginitis	P3	Completed	376	RCT, Double-blind	Ibrexafungerp, Placebo
NCT04029116 Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)	Recurrent Vulvovaginal Candidiasis	P3	Completed	440	RCT, Double-blind	Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet
NCT05178862 A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole	Candidiasis, Invasive, Candidemia	P3	Terminated	68	RCT, Double-blind	SCY-078, Fluconazole, Echinocandin
NCT03987620 Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis	Candida Vulvovaginitis	P3	Completed	455	RCT, Double-blind	Ibrexafungerp, Placebo
NCT03059992 Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment	Invasive Candidiasis, Mucocutaneous Candidiasis	P3	Completed	233	Open-label	Ibrexafungerp
NCT03363841 Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)	Candidiasis, Invasive, Candidemia	P3	Completed	30	Open-label	SCY-078
NCT02679456 Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis	Vulvovaginal Candidiasis	P2	Completed	96	RCT, Single-blind	SCY-078, Fluconazole
NCT03672292 Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis	Invasive Pulmonary Aspergillosis	P2	Terminated	22	RCT, Double-blind	SCY-078, Voriconazole
NCT01265511 Study of SCY-635, Pegasys and Copegus in Hepatitis C	Hepatitis C Infection	P2	Completed	10	RCT, Double-blind	Placebo, SCY-635, Pegasys, Copegus
NCT03253094 Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis	Candida Vulvovaginitis	P2	Completed	186	RCT, Double-blind	Fluconazole, SCY-078
NCT02244606 Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis	Mycoses, Candidiasis, Invasive	P2	Completed	27	RCT, Open-label	SCY-078, Fluconazole, Micafungin
NCT06954493 Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp	Vulvovaginal Candidiasis, Candida Infection	P1	Completed	5	Open-label	Ibrexafungerp
NCT04092751 Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects	Pharmacokinetics	P1	Completed	28	RCT, Open-label	PRA, SCY-078 plus PRA
NCT01290965 Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients	Chronic Hepatitis C	P1	Completed	57	RCT, Double-blind	Placebo, SCY-635
NCT04092725 Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects	Pharmacokinetics	P1	Completed	36	RCT, Open-label	DAB, SCY-078 plus DAB
NCT04307082 ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects	Fungal Infection	P1	Completed	6	Open-label	[14C]-Ibrexafungerp
NCT05668429 ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects	Fungal Disease	P1	Completed	6	Open-label	Ibrexafungerp